JO3044B1 - نظام تناول جرعة لمنبه مستقبل s1p - Google Patents
نظام تناول جرعة لمنبه مستقبل s1pInfo
- Publication number
- JO3044B1 JO3044B1 JOP/2009/0495A JOP20090495A JO3044B1 JO 3044 B1 JO3044 B1 JO 3044B1 JO P20090495 A JOP20090495 A JO P20090495A JO 3044 B1 JO3044 B1 JO 3044B1
- Authority
- JO
- Jordan
- Prior art keywords
- dosage regimen
- receptor agonist
- dosage
- daily dosage
- regimen
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Abstract
معدلات او منبهات مستقبل S1P يتم تعاطيها باتباع نظام تناول الجرعة والذي بمقتضاه خلال ايام المعالجة المبدئية تكون الجرعة اليومية أقل من الجرعة اليومية القياسية.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967308P | 2008-12-22 | 2008-12-22 | |
EP09167209 | 2009-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3044B1 true JO3044B1 (ar) | 2016-09-05 |
Family
ID=41435196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2009/0495A JO3044B1 (ar) | 2008-12-22 | 2009-12-21 | نظام تناول جرعة لمنبه مستقبل s1p |
Country Status (35)
Country | Link |
---|---|
US (2) | US8492441B2 (ar) |
EP (1) | EP2379069B1 (ar) |
JP (2) | JP5657565B2 (ar) |
KR (1) | KR101660555B1 (ar) |
CN (2) | CN102264363A (ar) |
AR (1) | AR074825A1 (ar) |
AU (1) | AU2009331582B2 (ar) |
BR (1) | BRPI0923213A2 (ar) |
CA (3) | CA2747992C (ar) |
CY (2) | CY1116321T1 (ar) |
DK (1) | DK2379069T3 (ar) |
ES (1) | ES2538413T3 (ar) |
FR (1) | FR20C1022I2 (ar) |
HK (1) | HK1159524A1 (ar) |
HR (1) | HRP20150567T1 (ar) |
HU (2) | HUE026400T2 (ar) |
IL (2) | IL294658A (ar) |
JO (1) | JO3044B1 (ar) |
LT (1) | LTC2379069I2 (ar) |
LU (1) | LUC00160I2 (ar) |
MA (1) | MA32907B1 (ar) |
MX (2) | MX2011006625A (ar) |
NL (1) | NL301046I2 (ar) |
NO (1) | NO2020017I1 (ar) |
NZ (1) | NZ593427A (ar) |
PL (1) | PL2379069T3 (ar) |
PT (1) | PT2379069E (ar) |
RU (1) | RU2561681C2 (ar) |
SG (1) | SG171888A1 (ar) |
SI (1) | SI2379069T1 (ar) |
TN (1) | TN2011000281A1 (ar) |
TW (1) | TWI472327B (ar) |
UY (1) | UY32350A (ar) |
WO (1) | WO2010072703A1 (ar) |
ZA (1) | ZA201104102B (ar) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104800208A (zh) | 2008-03-17 | 2015-07-29 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
DK2307007T3 (da) * | 2008-07-23 | 2014-11-10 | Novartis Ag | Sphingosin-1-phosphat-receptormodulatorer samt deres anvendelse til behandling af muskelinflammation |
EP3409274B1 (en) | 2008-12-22 | 2019-11-20 | Novartis AG | Dosage regimen for a s1p receptor agonist |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
EA201201515A1 (ru) * | 2010-05-06 | 2013-08-30 | Новартис Аг | Схема приема производных диарилсульфидов |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
PL2661261T3 (pl) | 2011-01-07 | 2020-01-31 | Novartis Ag | Formulacje immunosupresyjne |
WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
BR112014009141A8 (pt) * | 2011-10-21 | 2017-06-20 | Novartis Ag | regime de dosagem para um modulador ou agonista do receptor s1p |
CN104540800B (zh) | 2012-08-17 | 2017-05-10 | 埃科特莱茵药品有限公司 | 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物 |
EP4191245A3 (en) | 2013-04-04 | 2023-07-12 | Novartis AG | Identifying patient response to s1p receptor modulator administration |
JP6679495B2 (ja) * | 2014-04-10 | 2020-04-15 | ノバルティス アーゲー | 免疫抑制製剤 |
IL305337A (en) | 2014-04-10 | 2023-10-01 | Novartis Ag | A therapeutic regimen containing an immediate release dose of an S1P modulator |
KR20230147768A (ko) | 2014-12-11 | 2023-10-23 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
AU2016284162A1 (en) | 2015-06-22 | 2018-02-01 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders |
JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
CA3074416A1 (en) * | 2017-09-29 | 2019-04-04 | Novartis Ag | Dosing regimen of siponimod |
CA3073910A1 (en) * | 2017-09-29 | 2019-04-04 | Novartis Ag | Dosing regimen of siponimod |
WO2021084068A1 (en) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
MX2023009249A (es) | 2021-02-08 | 2023-10-23 | Bausch Health Ireland Ltd | Método para prevenir, tratar o mejorar la colitis ulcerosa. |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1176819A (zh) * | 1997-09-03 | 1998-03-25 | 王树生 | 一种解酒饮料及其制备方法 |
BR0311173A (pt) | 2002-05-16 | 2005-03-15 | Novartis Ag | Uso de agentes de ligação do receptor de edg em câncer |
MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
EP1628967B1 (en) | 2003-05-19 | 2014-04-09 | Irm Llc | Immunosuppressant compounds and compositions |
US20050095292A1 (en) * | 2003-10-29 | 2005-05-05 | Wyeth | Sustained release pharmaceutical compositions |
WO2005058316A1 (ja) | 2003-12-17 | 2005-06-30 | Dainippon Sumitomo Pharma Co., Ltd. | 合剤および併用剤 |
UA74941C2 (en) | 2004-04-26 | 2006-02-15 | Fos Internat S A | A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same |
WO2005113330A1 (en) | 2004-05-05 | 2005-12-01 | Adler, Richard, S. | Systems and methods for protecting ship from attack on the surface or under water |
NZ554720A (en) * | 2004-11-29 | 2011-04-29 | Novartis Ag | Compositions and uses of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol) |
US8795723B2 (en) * | 2005-09-09 | 2014-08-05 | Angelini Pharma Inc. | Sustained drug release compositions |
WO2008072056A1 (en) * | 2006-12-14 | 2008-06-19 | Pfizer Limited | Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation |
DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
SG187458A1 (en) * | 2007-10-12 | 2013-02-28 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
-
2009
- 2009-12-21 JO JOP/2009/0495A patent/JO3044B1/ar active
- 2009-12-21 RU RU2011129856/15A patent/RU2561681C2/ru active
- 2009-12-21 BR BRPI0923213A patent/BRPI0923213A2/pt not_active IP Right Cessation
- 2009-12-21 NZ NZ593427A patent/NZ593427A/xx not_active IP Right Cessation
- 2009-12-21 JP JP2011541496A patent/JP5657565B2/ja active Active
- 2009-12-21 AR ARP090105009A patent/AR074825A1/es unknown
- 2009-12-21 CN CN2009801519427A patent/CN102264363A/zh active Pending
- 2009-12-21 KR KR1020117017072A patent/KR101660555B1/ko active IP Right Grant
- 2009-12-21 ES ES09793546.4T patent/ES2538413T3/es active Active
- 2009-12-21 WO PCT/EP2009/067618 patent/WO2010072703A1/en active Application Filing
- 2009-12-21 EP EP09793546.4A patent/EP2379069B1/en active Active
- 2009-12-21 HU HUE09793546A patent/HUE026400T2/en unknown
- 2009-12-21 TW TW98143961A patent/TWI472327B/zh active
- 2009-12-21 CA CA2747992A patent/CA2747992C/en active Active
- 2009-12-21 DK DK09793546.4T patent/DK2379069T3/en active
- 2009-12-21 IL IL294658A patent/IL294658A/en unknown
- 2009-12-21 SG SG2011039765A patent/SG171888A1/en unknown
- 2009-12-21 PL PL09793546T patent/PL2379069T3/pl unknown
- 2009-12-21 SI SI200931199T patent/SI2379069T1/sl unknown
- 2009-12-21 AU AU2009331582A patent/AU2009331582B2/en active Active
- 2009-12-21 MX MX2011006625A patent/MX2011006625A/es active IP Right Grant
- 2009-12-21 CA CA2981830A patent/CA2981830A1/en not_active Abandoned
- 2009-12-21 CA CA3105857A patent/CA3105857C/en active Active
- 2009-12-21 MX MX2015011590A patent/MX367667B/es unknown
- 2009-12-21 PT PT97935464T patent/PT2379069E/pt unknown
- 2009-12-21 CN CN201510541635.7A patent/CN105213372A/zh active Pending
- 2009-12-21 UY UY0001032350A patent/UY32350A/es not_active Application Discontinuation
- 2009-12-22 US US12/655,049 patent/US8492441B2/en active Active
-
2011
- 2011-05-31 TN TN2011000281A patent/TN2011000281A1/fr unknown
- 2011-06-02 ZA ZA2011/04102A patent/ZA201104102B/en unknown
- 2011-06-02 IL IL21334711A patent/IL213347B/en active IP Right Grant
- 2011-06-17 MA MA33953A patent/MA32907B1/ar unknown
-
2012
- 2012-01-10 HK HK12100257.4A patent/HK1159524A1/xx unknown
-
2013
- 2013-06-18 US US13/920,406 patent/US20130281712A1/en active Pending
-
2014
- 2014-09-19 JP JP2014191541A patent/JP5941110B2/ja active Active
-
2015
- 2015-05-27 HR HRP20150567TT patent/HRP20150567T1/hr unknown
- 2015-05-27 CY CY20151100469T patent/CY1116321T1/el unknown
-
2020
- 2020-06-16 NL NL301046C patent/NL301046I2/nl unknown
- 2020-06-17 NO NO2020017C patent/NO2020017I1/no unknown
- 2020-06-17 HU HUS2000017C patent/HUS2000017I1/hu unknown
- 2020-06-18 LU LU00160C patent/LUC00160I2/fr unknown
- 2020-06-18 FR FR20C1022C patent/FR20C1022I2/fr active Active
- 2020-06-19 CY CY2020014C patent/CY2020014I1/el unknown
- 2020-06-23 LT LTPA2020513C patent/LTC2379069I2/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3044B1 (ar) | نظام تناول جرعة لمنبه مستقبل s1p | |
MX2021010759A (es) | Regimen de dosificacion para un agonista de los receptores de s1p. | |
PH12017501495A1 (en) | Dosage regimen of an s1p receptor modulator | |
MX2012000704A (es) | Agonistas de gpr119. | |
MX341025B (es) | Terapia de combinacion. | |
EA201190021A1 (ru) | Модуляторы toll-подобных рецепторов | |
MX2009006304A (es) | Nuevos compuestos de oxadiazol. | |
MX2007006373A (es) | Regimen de dosificacion de un agonista del receptor s1p. | |
MX2013007622A (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
MX2007010752A (es) | Usos oftalmicos de moduladores de receptor s1p. | |
TW200738269A (en) | Oral delivery of therapeutic agents using tight junction agonists | |
EA201390653A1 (ru) | Aa антагонисты как усилители когнитивной и моторной функций | |
CU20130155A7 (es) | Régimen de dosificación para un agonista de los receptores de s1p | |
MX2012012245A (es) | Combinacion de una reabsorcion de inhibidor de serotonina y norepirefrina y un agonista opioide para el tratamiento del dolor. | |
UA106219C2 (ru) | Модуляторы толл-подобных рецепторов |